The Company’s first-in-class therapeutic pipeline includes: MCT-125 for the treatment of chronic fatigue in MS patients. MCT-125 completed a 138 patient Phase II clinical trial and demonstrated strong efficacy in reducing fatigue in MS patients.  There is no drug specifically approved for the treatment of chronic fatigue in MS patients anywhere in the world. MCT-175 for the treatment of relapsing-remitting MS.  MCT-175, in preclinical development for the treatment of relapsing-remitting MS, targets disease specific autoaggressive T-cells that destroy the myelin sheath of nerve cells.  MCT-175 successfully ameliorated the disease in animal models.  MCT-275 for the treatment of type-1 diabetes. MCT-275, in preclinical development, targets disease-specific autoaggressive T-cells that destroy insulin producing cells in the pancreas.  MCT-275 completely reversed the type-1 diabetic phenotype and prolonged life in animal models.  MCT-465 for the treatment of virus infection. MCT-465 in preclinical studies successfully reduced pulmonary influenza virus levels 1,000-fold in animal models, and has demonstrated effectiveness in reducing virus levels of HIV and HCV in animal models. BioFactories™ Discovery Tools Products